AstraZeneca BioVenture Hub: A new way of building companies fast




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AstraZeneca BioVenture Hub: A new way of building companies fast
Released on: May 16, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Magus Bjorsne, CEO of AstraZeneca's BioVenture Hub, discusses how the capability, experience and expertise of AstraZeneca in helping mature Biotechs transition into product development.
  • Summary
  • Transcript
  • Participants
  • Company
Magus Bjorsne, CEO of AstraZeneca's BioVenture Hub, discusses how the capability, experience and expertise of AstraZeneca in helping mature Biotechs transition into product development.
Magus Bjorsne, CEO of AstraZeneca's BioVenture Hub, discusses how the capability, experience and expertise of AstraZeneca in helping mature Biotechs transition into product development.
Magnus Bjorsne
AstraZeneca
AstraZeneca plc is a British-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries (ICI), as three divisions that were spun off from ICI on 1 June 1993. It is a public company and is listed on the London Stock Exchange, the New York Stock Exchange and the OMX exchange.